AEGR Pengajuan SEC - Aegerion Pharmaceuticals, Inc.- Laporan Tahunan, Pernyataan Kuasa, Prospektus

Mga Batayang Estadistika

CIK

1338042

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Aegerion Pharmaceuticals, Inc.

SEC Filings (Chronological Order)

Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.

August 8, 2019	EX-99.T3A.15	Exhibit T3.A15 Exhibit T3A.15 CERTIFICATE OF INCORPORATION OF A PRIVATE LIMITED COMPANY Company Number 12107859 The Registrar of Companies for England and Wales, hereby certifies that AMRYT PHARMA HOLDINGS LIMITED is this day incorporated under the Companies Act 2006 as a private company, that the company is limited by shares, and the situation of its registered office is in England and Wales. Given at Companies
August 8, 2019	EX-99.T3B.2	Exhibit T3.B2 Exhibit T3B.2 BYLAWS OF AEGERION PHARMACEUTICALS HOLDINGS, INC. Section 1. LAW, CERTIFICATE OF INCORPORATION AND BYLAWS 1.1. These bylaws are subject to the certificate of incorporation of the corporation. In these bylaws, references to law, the certificate of incorporation and bylaws mean the law, the provisions of the certificate of incorporation and the bylaws as from time to time in effect. Se
August 8, 2019	EX-99.T3A.6	Exhibit T3.A6 Exhibit T3A.6 FORM No. 6 Registration No. 52048 BERMUDA CERTIFICATE OF INCORPORATION I hereby in accordance with section 14 of the Companies Act 1981 issue this Certificate of Incorporation and do certify that on the 18th day of November 2016 Aegerion International Ltd. was registered by me in the Register maintained by me under the provisions of the said section and that the status of the said co
August 8, 2019	EX-99.T3A.4	Exhibit T3.A4 Exhibit T3A.4 FORM NO. 6 Registration No. 46134 CERTIFICATE OF INCORPORATION I hereby in accordance with section 14 of the Companies Act 1981 issue this Certificate of Incorporation and do certify that on the 29th day of December 2011 Aegerion Pharmaceuticals Ltd. was registered by me in the Register maintained by me under the provisions of the said section and that the status of the said company
August 8, 2019	EX-99.T3A.16	Exhibit T3.A16 Exhibit T3A.16 FILE COPY CERTIFICATE OF INCORPORATION ON CHANGE OF NAME Company No. 5316808 The Registrar of Companies for England and Wales hereby certifies that ELM PARTNERS PLC having by special resolution changed its name, is now incorporated under the name of HAMILTON PARTNERS PLC Given at Companies House, London, the 4th December 2006 C053168083 FILE COPY CERTIFICATE OF INCORPORATION ON CH
August 8, 2019	EX-99.T3B.1	Exhibit T3.B1 Exhibit T3B.1 AMENDED AND RESTATED BYLAWS OF AEGERION PHARMACEUTICALS, INC. (the “Corporation”) SECTION 1 - STOCKHOLDERS Section 1.1. Annual Meeting. An annual meeting of the stockholders for the election of directors to succeed those whose terms expire and for the transaction of such other business as may properly come before the meeting shall be held at the place, if any, within or without the S
August 8, 2019	EX-99.T3A.21	Exhibit T3.A21 Exhibit T3A.21 Commercial Register B of district court Mannheim Retrieved on 22. July 2019 10:18 Company No. HRB 711487 Entry No. a) Business Name b) Registered Office, subsidiary, domestic business address, authorized recipient, branch offices c) Object of the Company Share capital a) General rules for representation b) Board of directors, Management Body, Managing Directors, personally liable pa
August 8, 2019	EX-99.T3A.18	Exhibit T3.A18 Exhibit T3A.18 Number 571411 Duplicate for the File Certificate of Incorporation I hereby certify that AMRYT RESEARCH LIMITED is this day incorporated under the Companies Act 2014, and that the company is a Private Company Limited by Shares. Given under my hand at Dublin, this Monday, the 9th day of November, 2015 /s/ Registrar for Registrar of Companies
August 8, 2019	EX-99.T3B.19	Exhibit T3.B19 Exhibit T3B.19 COMPANIES ACT 2014 CONSTITUTION OF AMRYT GENETICS LIMITED 1. The name of the Company is Amryt Genetics Limited (the “Company”). 2. The Company is a private company limited by shares registered under Part 2 of the Companies Act 2014 (the “Act”). 3. The liability of the members is limited. 4. The share capital of the Company is divided into Ordinary Shares of €1.00 each. 5. The “optio
August 8, 2019	EX-99.T3B.16	Exhibit T3.B16 EX-99.T3B.16 36 ex99t3b16.htm EXHIBIT T3B.16 Exhibit T3B.16 Company Number: 5316808 THE COMPANIES ACTS 1985 TO 2006 PUBLIC COMPANY LIMITED BY SHARES ARTICLES OF ASSOCIATION OF AMRYT PHARMA PLC (formerly known as Fastnet Equity Plc) (adopted by Special Resolution of the Members passed on 8 June 2012 and as amended by Special Resolution of the Members passed on 18 April 2016) Exhibit T3B.16 CONTENTS
August 8, 2019	EX-99.T3A.12	Exhibit T3.A12 Exhibit T3A.12 [Translation from the German language] Commercial register B of the Local Court [Amtsgericht] of Munich Called up on 18 July 2019, 2:00 pm Company registration no.: Page 1 of 2 HRB 226767 Entry no. a) Company name b) Registered office, permanent establishment, domestic business address, authorised recipient, branch offices c) Business object Share capital a) General rule of represen
August 8, 2019	EX-99.T3A.11	Exhibit T3.A11 Exhibit T3A.11 WRITING OF LIMITED COMPANY CONSTITUTION Y APPOINTMENT OF ADMINISTRATORS» NUMBER THREE HUNDRED THIRTY. In MADRID, my residence, on the twenty-ninth of January of two thousand eighteen. Before me, ISABEL ESTAPE TOUS, Notary of this Capital and the Illustrious College of Madrid. ====SHARE==== DON EDUARDO PÉREZ RANEDO, of legal age‑ domiciled for this purpose in Madrid(28046), Paseo de
August 8, 2019	EX-99.T3B.6	Exhibit T3.B6 Exhibit T3B.6 BYE-LAWS of Aegerion International Ltd. /s/ Susan Tindall For and on behalf of Codan Services Limited Secretary ADOPTED: 18th November, 2016 Standard exempted company Bye-laws BYE-LAWS OF Aegerion International Ltd. TABLE OF CONTENTS INTERPRETATION 1. Definitions SHARES 2. Power to Issue Shares 3. Power of the Company to Purchase its Shares 4. Rights Attaching to Shares 5. Calls on S
August 8, 2019	EX-99.T3B.7	Exhibit T3.A7 Exhibit T3B.7 Articles of Association of the company Aegerion Pharmaceuticals SARL with registered office in Eysins I. General Provisions Article 1: Corporate Name, Registered Office, Duration Under the corporate name Aegerion Pharmaceuticals SARL a limited liability company (the "Company") exists after to art. 772 and seq. of the Swiss Code of Obligations ("CO"), with its registered office in Eys
August 8, 2019	T-3/A	AEGR / Aegerion Pharmaceuticals, Inc. T-3/A - - T-3/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 1 to FORM T-3 FOR APPLICATIONS FOR QUALIFICATION OF INDENTURES UNDER THE TRUST INDENTURE ACT OF 1939 Aegerion Pharmaceuticals, Inc. and the Guarantors named herein (Name of Applicant) c/o Norton Rose Fulbright 1800 - 510 West Georgia Street, Vancouver, BC V6B 0M3 Canada (Address of principal executive offices) Se
August 8, 2019	EX-99.T3B.5	Exhibit T3.B5 Exhibit T3B.5 COMPANY HAVING A SHARE CAPITAL MEMORANDUM OF ASSOCIATION OF AEGERION PHARMACEUTICALS LIMITED Each subscriber to this memorandum of association wishes to form a company under the Companies Act 2006 and agrees to become a member of the company and to take at least one share. Name of each subscriber Authentication by each subscriber Aegerion Pharmaceuticals, Inc. Aegerion Pharmaceutical
August 8, 2019	EX-99.T3A.10	Exhibit T3.A10 Exhibit T3A.10 Number: BC0949808 CERTIFICATE OF INCORPORATION BUSINESS CORPORATIONS ACT I Hereby Certify that AEGERION PHARMACEUTICALS (CANADA) LTD. was incorporated under the Business Corporations Act on September 11, 2012 at 08:24 AM Pacific Time. Issued under my hand at Victoria, British Columbia On September 11, 2012 /s/ CAROL PREST CAROL PREST Registrar of Companies Province of British Columb
August 8, 2019	EX-99.T3A.5	Exhibit T3.A5 Exhibit T3A.5 CERTIFICATE OF INCORPORATION OF A PRIVATE LIMITED COMPANY Company Number. 8114919 The Registrar of Companies for England and Wales, hereby certifies that AEGERION PHARMACEUTICALS LIMITED is this day incorporated under the Companies Act 2006 as a private company, that the company is limited by shares, and the situation of its registered office is in England and Wales. Given at Compani
August 8, 2019	EX-99.T3B.15	Exhibit T3.B15 Exhibit T3B.15 Company Number: 12107859 The Companies Act 2006 PRIVATE COMPANY LIMITED BY SHARES ARTICLES OF ASSOCIATION Amryt Pharma Holdings Limited Incorporated on 17th July 2019 Vistra Limited www.vistra.com First Floor, Templeback 10 Temple Back Bristol BS1 6FL Tel: +44 (0)117 923 0600 Fax: +44 (0)117 923 0063 Exhibit T3B.15 THE COMPANIES ACT 2006 PRIVATE COMPANY LIMITED BY SHARES ARTICLES OF
August 8, 2019	EX-99.T3B.14	Exhibit T3.B14 Exhibit T3B.14 Directory n.4336 Collection n. 2625 CONSTITUTIVE ACT ITALIAN REPUBLIC The year two thousand twelve the twenty-ninth day of November in Rome and in my studio. 29 November 2012 Before me doctorMATILDE COVONE notary in Rome with study in Via Ravenna n. 15, registered in the Role of the Districts United Notaries of Rome, Velletri and Civitavecchia, IS PRESENT - THE LICATA PAOLA, born in
August 8, 2019	EX-99.T3B.10	Exhibit T3.B10 Exhibit T3B.10 Mailing Address: PO Box 9431 Stn Prov Govt Victoria BC V8W 9V3 www.corporateonline.gov.bc.ca Location: 2nd Floor - 940 Blanshard Street Victoria BC 1 877 526-1526 CERTIFIED COPY Of a Document filed with the Province of British Columbia Registrar of Companies Notice of Articles BUSINESS CORPORATIONS ACT CAROL PREST NOTICE OF ARTICLES Name of Company: AEGERION PHARMACEUTICALS (CANADA)
August 8, 2019	EX-99.T3B.4	Exhibit T3.B4 Exhibit T3B.4 BYE-LAWS of Aegerion Pharmaceuticals Ltd. For and on behalf of Codan Services Limited Secretary ADOPTED: 23rd February, 2012. Standard exempted company bye-laws BYE-LAWS OF Aegerion Pharmaceuticals Ltd. INTERPRETATION 1. Definitions SHARES 2. Power to Issue Shares 3. Power of the Company to Purchase its Shares 4. Rights Attaching to Shares 5. Calls on Shares 6. Prohibition on Financi
August 8, 2019	EX-99.T3A.14	Exhibit T3.A14 Exhibit T3A.14 This page shows an extract of the information present in the search which cannot be considered exhaustive, but which is purely for synthesis purposes HISTORICAL VISA CAPITAL COMPANY MILAN MONZA BRIANZA LODI Chamber of Commerce Business Register - Official Archive of the Chamber of Commerce AEGERION PHARMACEUTICALS SRL. 5089T1 The QR Code allows you to check the correspondence betwee
August 8, 2019	EX-99.T3A.17	Exhibit T3.A17 Exhibit T3A.17 Number 566448 Duplicate for the File Certificate of Incorporation I hereby certify that AMRYT PHARMACEUTICALS DESIGNATED ACTIVITY COMPANY is this day incorporated under the Companies Act 2014, and that the company is a Designated Activity Company Given under my hand at Dublin, this Monday, the 17th day of August, 2015 /s/ Registrar for Registrar of Companies
August 8, 2019	EX-99.T3B.18	Exhibit T3.B18 Exhibit T3B.18 COMPANIES ACT, 2014 CONSTITUTION OF AMRYT RESEARCH LIMITED 1. The name of the Company is Amryt Research Limited. 2. The Company is a private company limited by shares registered under Part 2 of the Companies Act 2014 (the “Act”). 3. The liability of the members is limited. 4. The share capital of the Company is 1,000,000 divided into 1,000,000 Ordinary Shares of €1.00 each. 5. The “
August 8, 2019	EX-99.T3B.8	Exhibit T3.B8 Exhibit T3B.8 2018/02/1918: It is current information Ark Mori Building 12F 1-12-32 Akasaka, Minato-ku, Tokyo AEGERION PHARMACEUTICALS K.K. Company corporation number 0104 – 01–107816 Business name AEGERION PHARMACEUTICALS K.K. Head office Ark Mori Building 12F 1-12-32 Akasaka, Minato-ku, Tokyo How to publicize Publish in the official gazette Year of the company establishment September 6, 2013 the
August 8, 2019	EX-99.T3A.20	Exhibit T3.A20 Exhibit T3A.20 Number 593833 Duplicate For File Certificate of Incorporation I hereby certify that AMRYT LIPIDOLOGY LIMITED is this day incorporated under the Companies Act 2014, and that the company is a Private Company Limited by Shares. Given under my hand at Dublin, this Wednesday, the 30th day of November, 2016 /s/ Registrar for Registrar of Companies
August 8, 2019	EX-99.T3B.3	Exhibit T3.B3 Exhibit T3B.3 BY-LAWS of AEGERION SECURITIES CORPORATION Section 1. ARTICLES OF ORGANIZATION The name and purposes of the corporation shall be as set forth in the Articles of Organization. These By-laws, the powers of the corporation and of its board of directors and shareholders, or of any class of shareholders if the corporation has more than one class of shares, and all matters concerning the c
August 8, 2019	EX-99.T3B.13	Exhibit T3.B13 Exhibit T3B.13 JUCESP 21 10 11 22 ARTICLES OF ASSOCIATION OF JINOTEPE PARTICIPAÇÕES LTDA. By this private instrument (a) FS ADMINISTRAÇÃO DE BENS E PARTICIPAÇÕES LTDA., Brazilian limited liability company with its principal place of business in the City of São Paulo, State of São Paulo, at Rua Boa Vista, 254, 16º andar, sala 1608, Centro – CEP 01014-000, enrolled in the National Register of Legal
August 8, 2019	EX-99.T3A.3	Exhibit T3.A3 Exhibit T3A.3 The Commonwealth of Massachusetts William Francis Galvin Secretary of the Commonwealth One Ashburton Place, Boston, Massachusetts 02108-1512 FORM MUST BE TYPED Articles of Organization FORM MUST BE TYPED (General Laws Chapter 156D, Section 2.02; 950 CMR 113.16) ARTICLE I The exact name of the corporation is: Aegerion Securities Corporation ARTICLE II Unless the articles of organizati
August 8, 2019	EX-99.T3B.21	Exhibit T3.B21 Exhibit T3B.21 I. Allgemeine Bestimmungen § 1 Firma, Sitz und Geschäftsjahr (1) Die Gesellschaft führt die Firma Amryt AG. (2) Sie hat ihren Sitz in 75223 Niefern-Öschelbronn. (3) Das Geschäftsjahr der Gesellschaft ist das Kalenderjahr. Das erste Geschäftsjahr ist ein Rumpfgeschäftsjahr, welches mit der Eintragung des Formwechsels in das Handelsregister beginnt und dem darauf folgenden 31.12. ende
August 8, 2019	EX-99.T3B.12	Exhibit T3.B12 Exhibit T3B.12 1036 URNr. / 2016 from 23. May 2016 Certificate according to § 54 Abs. 1 sentence 2 GmbHG Due to § 54 Abs. 1 sentence 2 of the Limited Liability Companies Act (Limited Liability Company Act), I hereby certify that the text below is the company's articles of incorporation Aegerion Pharmaceuticals GmbH with the seat in Munich reflects how he is after the decision on the amendment of t
August 8, 2019	EX-99.T3A.13	Exhibit T3.A13 Exhibit T3A.13 REGISTRATION DATA NIRE FROM HEADQUARTERS BAR CODE (NIRE) CNPJ HEADQUARTERS NO PREVIOUS REQUIREMENT 3522602510-1 14,555,259/0001-03 ACT (S) REGISTERED Inclusion / Alteration of Members; ER.CIESP ACT (S) AEGERION BRASIL SALES PROMOTION AND ADMINISTRATION SERVICES LTDA. PUBLIC PLACE NUMBER Paulista Avenue 2300 COMPLEMENT NEIGHBORHOOD / DISTRICT Zip code CODE OF THE CITY Pilotis floor,
August 8, 2019	EX-99.T3B.20	Exhibit T3.B20 Exhibit T3B.20 Companies Act 2019. Section 19 FORM OF CONSTITUTION OF PRIVATE COMPANY LIMITED BY SHARES CONSTITUTION OF [name of company as below] 1. The name of the company is AMRYT LIPIDOLOGY LIMITED 2. The company is a private company limited by shares, registered under Part 2 of the Companies Act 2014. 3. The liability of the members is limited. 4. The share capital of the company is EUR 10000
August 8, 2019	EX-99.T3A.19	Exhibit T3.A19 Exhibit T3A.19 Number 622577 Duplicate For File Certificate of Incorporation I hereby certify that AMRYT GENETICS LIMITED is this day incorporated under the Companies Act 2014, and that the company is a Private Company Limited by Shares. Given under my hand at Dublin, this Monday, the 12th day of March, 2018 /s/ Registrar for Registrar of Companies
August 8, 2019	EX-99.T3A.8	Exhibit T3.A8 Exhibit T3A.8 Original AEGERION PHARMACEUTICALS K.K. Articles of Incorporation 1 AEGERION PHARMACEUTICALS K.K. Articles of Incorporation Second 1 Chapter General Rule Second Article 1 (Trade name) Our company is AEGERION PHARMACEUTICALS. It is called a corporation. Second Article 2 (Purpose) The company aims to conduct the following business. 1. Research, development, manufacture, sales, commercia
August 8, 2019	EX-99.T3A.9	Exhibit T3.A9 Exhibit T3A.9 Registry of the Commercial Court of Nanterre 4 PABLO NERUDA STREET 92020 NANTERRE CEDEX Management No. 2018B01400 Verification code: 54fd56n7X6 https://www.infogreffe.fr/controle Preview MAIN REGISTRATION EXTRACT FROM THE TRADE AND SOCIETY REGISTER as of July 17, 2019 IDENTIFICATION OF THE MORAL PERSON RCS registration, number 534 195 599 RCS. Nanterre Date of registration 08/02/2018
August 8, 2019	EX-99.T3B.9	Exhibit T3.B9 Exhibit T3B.9 AEGERION PHARMACEUTICALS Joint stock company with a capital of 30,000 euros The head office: 235, avenue le Jour Se Lives - 92100 Boulogne- Billancourt 534 195 599 RCS Nanterre CONSTITUTION updated on January 12, 2018 Certified copy Barbara Chan President CONSTITUTION ARTICLE 1: FORM The company has the form of a simplified joint-stock company. The Company will have one or more partn
August 8, 2019	EX-99.T3A.2	Exhibit T3.A2 Exhibit T3A.2 CERTIFICATE OF INCORPORATION OF AEGERION PHARMACEUTICALS HOLDINGS, INC. ARTICLE I The name of the corporation is AEGERION PHARMACEUTICALS HOLDINGS, INC. (the “Corporation”). ARTICLE II The address of the Corporation’s registered office in the State of Delaware is 2711 Centerville Road, Suite 400, City of Wilmington, County of New Castle, Delaware 19808. The name of its registered age
August 8, 2019	EX-99.T3B.11	Exhibit T3.B11 Exhibit T3B.11 Bylaws of AEGERION PHARMACEUTICALS SPAIN, S.L. Title I Name, Purpose, Registered Office and Duration of the Company Article 1.- Company Name The name of the Company is AEGERION PHARMACEUTICALS SPAIN, S.L. (or Sociedad Limitada, or S.R.L. or Sociedad de Responsabilidad Limitada) and will be governed by the provisions included within these by-laws and, in the absence thereof, those in
August 8, 2019	EX-99.T3B.17	Exhibit T3.B17 Exhibit T3B.17 Companies Act 2014 DESIGNATED ACTIVITY COMPANY LIMITED BY SHARES CONSTITUTION OF AMRYT PHARMACEUTICALS DESIGNATED ACTIVITY COMPANY (as adopted by Special Resolution No. 3 on 9 October, 2015) MEMORANDUM OF ASSOCIATION 1. The name of the Company is AMRYT PHARMACEUTICALS DESIGNATED ACTIVITY COMPANY 2. The company is a designated activity company limited by shares, that is to say a priv
August 7, 2019	CORRESP	AEGR / Aegerion Pharmaceuticals, Inc. CORRESP - - Aegerion Pharmaceuticals, Inc. One Main Street, Suite 800 Cambridge, MA 02142 VIA EDGAR August 7, 2019 Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 Attention: Mr. Jeffrey Gabor Re: Aegerion Pharmaceuticals, Inc. Form T-3 (File No. 022-29077) Ladies and Gentlemen: This letter is sent on behalf of Aegerion Pharmaceuticals, Inc. (the
July 19, 2019	EX-25.1	Exhibit 25.1 Exhibit 25.1 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE ☐ CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTEE PURSUANT TO SECTION 305(b) (2) GLAS TRUST COMPANY LLC (Exact name of trustee as specified in its charter) A New Hampshire Limited Liability Company
July 19, 2019	EX-99.T3C.1	Exhibit T3F.1 Exhibit T3C.1 AEGERION PHARMACEUTICALS. INC., THE GUARANTOR PARTIES HERETO and [TRUSTEE’S LEGAL NAME] as Trustee INDENTURE Dated as of [closing date] 5.00% Convertible Senior Notes due [maturity year]* * Insert the calendar year of the 11th scheduled Interest Payment Date. CROSS REFERENCE TABLE* Trust Indenture Act Section Indenture Section 310 (a)(1) 11.09 (a)(2) 11.09 (a)(3) N/A (a)(4) N/A (a)(5
July 19, 2019	T-3	AEGR / Aegerion Pharmaceuticals, Inc. T-3 - - T-3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM T-3 FOR APPLICATIONS FOR QUALIFICATION OF INDENTURES UNDER THE TRUST INDENTURE ACT OF 1939 Aegerion Pharmaceuticals, Inc. (Name of Applicant) c/o Norton Rose Fulbright 1800 - 510 West Georgia Street, Vancouver, BC V6B 0M3 Canada (Address of principal executive offices) Securities to be Issued under the Indenture to be Qua
February 14, 2017	SC 13G/A	AEGR / Aegerion Pharmaceuticals, Inc. / ARMISTICE CAPITAL, LLC Passive Investment SC 13G/A 1 d741338213g-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Aegerion Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 00767E102 (CUSIP Number) December 31, 2016 (Date of Event Which Requires Filing of this Statement) Check th
February 8, 2017	SC 13G/A	AEGR / Aegerion Pharmaceuticals, Inc. / INTEGRATED CORE STRATEGIES (US) LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 3) AEGERION PHARMACEUTICALS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 00767E102 (CUSIP Number) DECEMBER 31, 2016 (Date of event which requires filing of this statement) Check the appropriate box to designa
January 31, 2017	SC 13G/A	AEGR / Aegerion Pharmaceuticals, Inc. / Athyrium Opportunities II Acquisition LP - SCHEDULE 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to Rules 13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to Rule 13d-2(b) (Amendment No.
December 9, 2016	15-12B	Aegerion Pharmaceuticals 15-12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-34921 AEGERION PHARMACEUTICALS, INC. (Exact name of registrant as specif
December 5, 2016	SC 13G/A	AEGR / Aegerion Pharmaceuticals, Inc. / SCOPIA CAPITAL MANAGEMENT LP - SCHEDULE 13G Passive Investment SC 13G/A 1 e72146sc13g-a.htm SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* Aegerion Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 00767E102 (CUSIP Number) November 29, 2016 (Date of Event Which Requires Filing of this Statement) Check
December 1, 2016	SC 13D/A	AEGR / Aegerion Pharmaceuticals, Inc. / Broadfin Capital, LLC Activist Investment SC 13D/A 1 d7353969sc13d-a2.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* Aegerion Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 00767E102 (CUSIP Number) Broadfin Capital, LLC 300 Park Avenue, 25th Floor New York, New York 10022 Telephone- (212) 808
November 30, 2016	SC 13D/A	AEGR / Aegerion Pharmaceuticals, Inc. / Sarissa Capital Management LP - SCHEDULE 13D/A, #7 Activist Investment SC 13D/A 1 s18770296.htm SCHEDULE 13D/A, #7 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 7)* Aegerion Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 00767E102 (CUSIP Number) Mark DiPaolo General Counsel Sarissa Capital Management LP 660 Steamboat Road G
November 29, 2016	EX-3.1	Exhibit T3.A1 Exhibit 3.1 FIFTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF AEGERION PHARMACEUTICALS, INC. ARTICLE I ? NAME The name of the Corporation is Aegerion Pharmaceuticals, Inc. ARTICLE II ? REGISTERED OFFICE AND AGENT The address of the Corporation?s registered office in the State of Delaware is 2711 Centerville Road, Suite 400, in the City of Wilmington, County of New Castle. The name of the
November 29, 2016	8-K	Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Material Modification to Rights of Security Holders, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 25, 2016 AEGERION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34921 20-2960116 (State or other jurisdiction of incorporation) (C
November 29, 2016	EX-3.2	AMENDED AND RESTATED AEGERION PHARMACEUTICALS, INC. (the “Corporation”) SECTION 1 - STOCKHOLDERS Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF AEGERION PHARMACEUTICALS, INC. (the ?Corporation?) SECTION 1 - STOCKHOLDERS Section 1.1. Annual Meeting. An annual meeting of the stockholders for the election of directors to succeed those whose terms expire and for the transaction of such other business as may properly come before the meeting shall be held at the place, if any, within or without the Sta
November 29, 2016	EX-4.1	SUPPLEMENTAL INDENTURE EX-4.1 4 a16-219749ex4d1.htm EX-4.1 Exhibit 4.1 SUPPLEMENTAL INDENTURE This Supplemental Indenture (this “Supplemental Indenture”) is dated as of November 29, 2016, by and between Aegerion Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and The Bank of New York Mellon Trust Company, N.A., a national banking association, as Trustee (the “Trustee”). W I T N E S S E T H WHEREAS, the Co
November 29, 2016	POS AM	Aegerion Pharmaceuticals POS AM As filed with the Securities and Exchange Commission on November 29, 2016 Registration No.
November 29, 2016	S-8 POS	Aegerion Pharmaceuticals S-8 POS As filed with the Securities and Exchange Commission on November 29, 2016 Registration No.
November 29, 2016	S-8 POS	Aegerion Pharmaceuticals S-8 POS As filed with the Securities and Exchange Commission on November 29, 2016 Registration No.
November 29, 2016	S-8 POS	Aegerion Pharmaceuticals S-8 POS As filed with the Securities and Exchange Commission on November 29, 2016 Registration No.
November 29, 2016	S-8 POS	Aegerion Pharmaceuticals S-8 POS As filed with the Securities and Exchange Commission on November 29, 2016 Registration No.
November 29, 2016	S-8 POS	Aegerion Pharmaceuticals S-8 POS As filed with the Securities and Exchange Commission on November 29, 2016 Registration No.
November 29, 2016	S-8 POS	Aegerion Pharmaceuticals S-8 POS As filed with the Securities and Exchange Commission on November 29, 2016 Registration No.
November 16, 2016	SC 13G	AEGR / Aegerion Pharmaceuticals, Inc. / ARMISTICE CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
November 7, 2016	8-K	Submission of Matters to a Vote of Security Holders Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): November 7, 2016 AEGERION PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-34921 22-2960116 (State of Other Jurisdiction of Incorpora
November 4, 2016	10-Q	Aegerion Pharmaceuticals 10-Q (Quarterly Report) Document Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.
November 4, 2016	EX-24	POWER OF ATTORNEY Exhibit 24 POWER OF ATTORNEY The undersigned hereby constitutes and appoints Benjamin Harshbarger, Greg Perry, Paul Kinsella and Jennifer Fitzpatrick, with full power of substitution, as the undersigned?s true and lawful attorney-in-fact to: (1) prepare, execute in the undersigned?s name and on the undersigned?s behalf, and submit to the U.
November 4, 2016	EX-10.1	SIXTH AMENDMENT TO FORBEARANCE AGREEMENT EX-10.1 2 exhibit101.htm EXHIBIT 10.1 Exhibit 10.1 SIXTH AMENDMENT TO FORBEARANCE AGREEMENT THIS SIXTH AMENDMENT TO FORBEARANCE AGREEMENT (this “Amendment”) is made as of this 30th day of September, 2016 by and between SILICON VALLEY BANK, a California corporation, with its principal place of business at 3003 Tasman Drive, Santa Clara, California 95054 and with a loan production office located at
November 4, 2016	EX-10.3	FIFTH AMENDMENT TO LEASE Exhibit 10.3 FIFTH AMENDMENT TO LEASE THIS FIFTH AMENDMENT TO LEASE, dated as of July 19, 2016 (this “Amendment”), between RREEF AMERICA REIT II CORP. PPP, a Maryland corporation (“Landlord”), and AEGERION PHARMACEUTICALS, INC., a Delaware corporation (“Tenant”), for certain premises located in two buildings in Riverfront Office Park, Cambridge, Massachusetts at 101 Main Street (the “101 Main Buil
November 4, 2016	EX-10.2	EMPLOYMENT AGREEMENT Exhibit 10.2 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) is made and entered into as of this 21st day of September, 2016, by and between Aegerion Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Remi Menes (the “Employee”). W I T N E S S E T H : WHEREAS, the Company desires to employ Employee and desires to enter into this Agreement embodying the terms of su
November 3, 2016	EX-99.1	AEGERION PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2016 FINANCIAL RESULTS - Company records $35.4 million in total net product sales -- Exhibit Exhibit 99.1 AEGERION PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2016 FINANCIAL RESULTS - Company records $35.4 million in total net product sales - Cambridge, MA, November 3, 2016 - Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, announced its fi
November 3, 2016	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): November 3, 2016 AEGERION PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-34921 22-2960116 (State of Other Jurisdiction of Incorpora
October 24, 2016	8-K	Aegerion Pharmaceuticals 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 21, 2016 AEGERION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34921 20-2960116 (State or other jurisdiction of incorporation) (Co
October 24, 2016	425	Aegerion Pharmaceuticals 8-K (Prospectus) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 21, 2016 AEGERION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34921 20-2960116 (State or other jurisdiction of incorporation) (Co
October 20, 2016	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 20, 2016 AEGERION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34921 20-2960116 (State or other jurisdiction (Commission (IRS Empl
October 20, 2016	425	Aegerion Pharmaceuticals 8-K (Prospectus) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 20, 2016 AEGERION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34921 20-2960116 (State or other jurisdiction (Commission (IRS Empl
October 6, 2016	DEFM14A	Aegerion Pharmaceuticals DEFM14A Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
October 3, 2016	8-K	Financial Statements and Exhibits, Other Events 8-K 1 a16-1933918k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 28, 2016 AEGERION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34921 20-2960116 (State or other juris
October 3, 2016	EX-99.1	Aegerion Pharmaceuticals JUXTAPID® (lomitapide) Capsules Approved in Japan for the Treatment of Homozygous Familial Hypercholesterolemia (HoFH) EX-99.1 2 a16-193391ex99d1.htm EX-99.1 Exhibit 99.1 Aegerion Pharmaceuticals’ JUXTAPID® (lomitapide) Capsules Approved in Japan for the Treatment of Homozygous Familial Hypercholesterolemia (HoFH) Cambridge, MA, September 28, 2016 - Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with
September 20, 2016	EX-24	POWER OF ATTORNEY Exhibit 24 POWER OF ATTORNEY The undersigned hereby constitutes and appoints Benjamin Harshbarger, Greg Perry, Paul Kinsella and Jennifer Fitzpatrick, with full power of substitution, as the undersigned?s true and lawful attorney-in-fact to: (1) prepare, execute in the undersigned?s name and on the undersigned?s behalf, and submit to the U.
September 13, 2016	SC 13D/A	AEGR / Aegerion Pharmaceuticals, Inc. / Broadfin Capital, LLC Activist Investment SC 13D/A 1 d7255714sc13d-a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Aegerion Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 00767E102 (CUSIP Number) Broadfin Capital, LLC 300 Park Avenue, 25th Floor New York, New York 10022 Telephone- (212) 808
September 12, 2016	425	Aegerion Pharmaceuticals 425 (Prospectus) Filed by Aegerion Pharmaceuticals, Inc. pursuant to Rule 425 Under the Securities Act of 1933 Deemed filed pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Aegerion Pharmaceuticals, Inc. Commission File No. 001-34921 Dear colleagues, I am sure that everyone has been eagerly awaiting an update regarding the pending merger of Aegerion and QLT since our announcement
September 8, 2016	EX-24	POWER OF ATTORNEY Exhibit 24 POWER OF ATTORNEY The undersigned hereby constitutes and appoints Benjamin Harshbarger, Greg Perry, Paul Kinsella and Jennifer Fitzpatrick, with full power of substitution, as the undersigned?s true and lawful attorney-in-fact to: (1) prepare, execute in the undersigned?s name and on the undersigned?s behalf, and submit to the U.
August 10, 2016	425	Aegerion Pharmaceuticals 425 (Prospectus) Filed by Aegerion Pharmaceuticals, Inc. pursuant to Rule 425 Under the Securities Act of 1933 Deemed filed pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Aegerion Pharmaceuticals, Inc. Commission File No. 001-34921 August 9, 2016 Second Quarter 2016 Financial Results Forward-Looking Statements This press release contains forward-looking statements, including sta
August 9, 2016	425	Aegerion Pharmaceuticals (Prospectus) aegrCurrentFolio425earningsrelease Filed by Aegerion Pharmaceuticals, Inc. pursuant to Rule 425 Under the Securities Act of 1933 Deemed filed pursuant to Rule14a-12 Under the Securities Exchange Act of 1934 Subject Company: Aegerion Pharmaceuticals, Inc. Commission File No. 001-34921 AEGERION PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2016 FINANCIAL RESULTS  Company records $44.5 million in total n
August 9, 2016	425	Aegerion Pharmaceuticals (Prospectus) aegrCurrentFolio425earningsrelease Filed by Aegerion Pharmaceuticals, Inc. pursuant to Rule 425 Under the Securities Act of 1933 Deemed filed pursuant to Rule14a-12 Under the Securities Exchange Act of 1934 Subject Company: Aegerion Pharmaceuticals, Inc. Commission File No. 001-34921 AEGERION PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2016 FINANCIAL RESULTS  Company records $44.5 million in total n
August 9, 2016	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): August 9, 2016 AEGERION PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-34921 22-2960116 (State of Other Jurisdiction of Incorporation) (Comm
August 9, 2016	EX-99.1	AEGERION PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2016 FINANCIAL RESULTS  Company records $44.5 million in total net product sales --  Company reiterates 2016 total net product sales guidance of between $130 and $150 million -- aegrEX991 Exhibit 99.1 AEGERION PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2016 FINANCIAL RESULTS ? Company records $44.5 million in total net product sales - ? Company reiterates 2016 total net product sales guidance of between $130 and $150 million - Cambridge, MA, August 9, 2016 - Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR), a biopharmaceutical company dedicated to the development and commercia
August 9, 2016	10-Q	Aegerion Pharmaceuticals 10-Q (Quarterly Report) aegrCurrent Folio10Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.
August 9, 2016	EX-10.7	Annual Retainer Exhibit 10.7 AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The purpose of this Amended and Restated Non-Employee Director Compensation Policy (this “Policy”) of Aegerion Pharmaceuticals, Inc., a Delaware corporation (the “Corporation”), is to provide a total compensation package that enables the Corporation to attract and retain, on a long-term basis, high caliber directors who ar
August 8, 2016	8-K	Financial Statements and Exhibits, Other Events 8-K 1 a16-1615118k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2016 AEGERION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34921 20-2960116 (State or other jurisdict
August 8, 2016	EX-99.1	1 Exhibit 99.1 RISK FACTORS Risks Associated with Product Development and Commercialization Our business depends on the success of lomitapide. We may not be able to meet expectations with respect to sales of lomitapide and revenues from such sales, and if we are not able to meet such expectations, we may not be able to attain or maintain positive cash flow and profitability in the time periods we an
July 20, 2016	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Costs Associated with Exit or Disposal Activities UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 14, 2016 AEGERION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34921 20-2960116 (State or other jurisdiction of incorporation) (Commi
July 20, 2016	EX-99.1	AEGERION PHARMACEUTICALS ANNOUNCES COST REDUCTION PLANS - Company announces revision to lomitapide ex-U.S. strategy and reduction in global workforce Exhibit 99.1 FOR IMMEDIATE RELEASE AEGERION PHARMACEUTICALS ANNOUNCES COST REDUCTION PLANS - Company announces revision to lomitapide ex-U.S. strategy and reduction in global workforce Cambridge, MA, July 20, 2016 - Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rar
July 5, 2016	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2016 AEGERION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34921 20-2960116 (State or other jurisdiction of incorporation) (Commi
June 24, 2016	SC 13D	NVLN / NOVELION THERAPEUTICS INC. / Aegerion Pharmaceuticals, Inc. - SC 13D Activist Investment SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 QLT Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 746927102 (CUSIP Number) Benjamin Harshbarger Acting General Counsel Aegerion Pharmaceuticals, Inc. One Main Street, Suite 800 Cambridge, MA 02142 (617) 500-7867 (Name, Address and Telephone Numb
June 23, 2016	SC 13D	AEGR / Aegerion Pharmaceuticals, Inc. / QLT INC/BC - SC 13D/A Activist Investment SC 13D 1 a16-138801sc13d.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Aegerion Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 00767E102 (CUSIP Number) Glen Ibbott Chief Financial Officer QLT Inc. 887 Great Northern Way, Sui
June 22, 2016	SC 13D	AEGR / Aegerion Pharmaceuticals, Inc. / Broadfin Capital, LLC Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.
June 21, 2016	425	Aegerion Pharmaceuticals 425 (Prospectus) Filed by Aegerion Pharmaceuticals, Inc. pursuant to Rule 425 Under the Securities Act of 1933 Deemed filed pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Aegerion Pharmaceuticals, Inc. Commission File No. 001-34921 Hi everyone, As everyone is aware by now, Aegerion and QLT Inc. announced last week that they have entered into a definitive merger agreement under w
June 17, 2016	EX-10.5	VOTING AGREEMENT Exhibit 10.5 VOTING AGREEMENT This VOTING AGREEMENT (this Voting Agreement), dated as of June 14, 2016, by and between QLT Inc., a corporation incorporated under the laws of British Columbia (QLT), and Broadfin Healthcare Master Fund LTD, a Cayman Islands limited company (the Stockholder). W I T N E S S E T H: WHEREAS, concurrently with the execution of this Voting Agreement, Aegerion Pharma
June 17, 2016	425	Aegerion Pharmaceuticals 8-K/A (Prospectus) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A Amendment No. 1 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 14, 2016 QLT Inc. (Exact Name of Registrant as specified in its charter) British Columbia, Canada 000-17082 N/A (State or Other Jurisdiction of Incorporation) (
June 16, 2016	425	Aegerion Pharmaceuticals 425 (Prospectus) Filed by Aegerion Pharmaceuticals, Inc. pursuant to Rule 425 Under the Securities Act of 1933 Deemed filed pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Aegerion Pharmaceuticals, Inc. Commission File No. 001-34921 Aegerion Pharmaceuticals One Main Street, Suite 800 Cambridge, MA 02142 www.aegerion.com June 16, 2016 Dear QLT Employees, We at Aegerion have the hi
June 16, 2016	425	Aegerion Pharmaceuticals 425 (Prospectus) Filed by QLT Inc. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934. Subject Company: Aegerion Pharmaceuticals, Inc. Commission File No.: 001-34921 Aegerion Pharmaceuticals One Main Street, Suite 800 Cambridge, MA 02142 www.aegerion.com June 16, 2016 Dear QLT Employees, We at Aegerion have the highest regard for al
June 16, 2016	EX-10.6	VOTING AGREEMENT Exhibit 10.6 VOTING AGREEMENT This VOTING AGREEMENT (this Voting Agreement), dated as of June 14, 2016, by and between QLT Inc., a corporation incorporated under the laws of British Columbia (QLT), and Sarissa Capital Domestic Fund LP, a Delaware limited partnership and Sarissa Capital Offshore Master Fund LP, a Cayman Islands exempted limited partnership (together, the Stockholder). W I T N
June 16, 2016	425	Aegerion Pharmaceuticals 8-K (Prospectus) 425 1 a16-1339128k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 14, 2016 QLT Inc. (Exact Name of Registrant as specified in its charter) British Columbia, Canada 000-17082 N/A (State or Other Jurisdiction of Incorpo
June 16, 2016	EX-10.1	UNIT SUBSCRIPTION AGREEMENT by and among QLT INC. THE INVESTORS IDENTIFIED ON SCHEDULE I HERETO Dated as of June 14, 2016 Exhibit 10.1 Execution Version UNIT SUBSCRIPTION AGREEMENT by and among QLT INC. and THE INVESTORS IDENTIFIED ON SCHEDULE I HERETO Dated as of June 14, 2016 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 1 1.1 CERTAIN DEFINITIONS 1 1.2 TERMS DEFINED ELSEWHERE IN THIS AGREEMENT 3 1.3 OTHER DEFINITIONAL AND INTERPRETIVE MATTERS 3 ARTICLE II SUBSCRIPTION FOR UNITS; SUBSCRIPTION PRICE; INVESTMENT CLOSIN
June 16, 2016	SC 13D/A	Aegerion Pharmaceuticals SCHEDULE 13D/A, AMENDMENT #6 (Activist Acquisition of More Than 5% of Shares) CUSIP No. 00767E102 Page 1 of 8 Pages SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 6)* Aegerion Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 00767E102 (CUSIP Number) Mark DiPaolo General Counsel Sarissa Capital Management LP 660 Steam
June 16, 2016	EX-1	VOTING AGREEMENT VOTING AGREEMENT This VOTING AGREEMENT (this ? Voting Agreement?), dated as of June 14, 2016, by and between QLT Inc.
June 15, 2016	425	Aegerion Pharmaceuticals 425 (Prospectus) Filed by QLT Inc. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934. Subject Company: Aegerion Pharmaceuticals, Inc. Commission File No.: 001-34921 Aegerion and QLT A Compelling June 15, 2016 Rare Disease Opportunity Mary Szela, Aegerion Pharmaceuticals, Inc. CEO Gregory Perry, Aegerion Pharmaceuticals, Inc. CFO Dr
June 15, 2016	425	Aegerion Pharmaceuticals 425 (Prospectus) Filed by Aegerion Pharmaceuticals, Inc. pursuant to Rule 425 Under the Securities Act of 1933 Deemed filed pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Aegerion Pharmaceuticals, Inc. Commission File No. 001-34921 Aegerion and QLT A Compelling June 15, 2016 Rare Disease Opportunity Mary Szela, Aegerion Pharmaceuticals, Inc. CEO Gregory Perry, Aegerion Pharmaceu
June 15, 2016	425	Aegerion Pharmaceuticals 425 (Prospectus) Filed by QLT Inc. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934. Subject Company: Aegerion Pharmaceuticals, Inc. Commission File No.: 001-34921 THOMSON REUTERS STREETEVENTS EDITED TRANSCRIPT AEGR - Aegerion Pharmaceuticals Inc & QLT Inc Agree to Strategic Merger Call EVENT DATE/TIME: JUNE 15, 2016 / 12:30PM GMT
June 15, 2016	425	Aegerion Pharmaceuticals 8-K (Prospectus) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 15, 2016 QLT Inc. (Exact Name of Registrant as specified in its charter) British Columbia, Canada 000-17082 N/A (State or Other Jurisdiction of Incorporation) (Commission File Nu
June 15, 2016	EX-99.1	AEGERION PHARMACEUTICALS AND QLT INC. AGREE TO STRATEGIC MERGER —Strategic Merger Creates Well-Capitalized, Global Biopharmaceutical Organization with Diverse Portfolio of Two Commercialized Rare Disease Programs and a Phase 3 Ready Ultra-Orphan Deve EX-99.1 2 a16-133911ex99d1.htm EX-99.1 Exhibit 99.1 AEGERION PHARMACEUTICALS AND QLT INC. AGREE TO STRATEGIC MERGER —Strategic Merger Creates Well-Capitalized, Global Biopharmaceutical Organization with Diverse Portfolio of Two Commercialized Rare Disease Programs and a Phase 3 Ready Ultra-Orphan Development Program Addressing Significant Unmet Medical Need— —Broad-Based Investor Syndicate to Vote
June 15, 2016	EX-10.5	FOURTH AMENDMENT TO FORBEARANCE AGREEMENT Exhibit 10.5 FOURTH AMENDMENT TO FORBEARANCE AGREEMENT THIS FOURTH AMENDMENT TO FORBEARANCE AGREEMENT (this ?Amendment?) is made as of this 8th day of June, 2016 by and between SILICON VALLEY BANK, a California corporation, with its principal place of business at 3003 Tasman Drive, Santa Clara, California 95054 and with a loan production office located at 275 Grove Street, Suite 2-200, Newton, Mas
June 15, 2016	EX-10.3	SEVENTH LOAN MODIFICATION AGREEMENT Exhibit 10.3 SEVENTH LOAN MODIFICATION AGREEMENT This Seventh Loan Modification Agreement (this ?Loan Modification Agreement?) is entered into as of June 14, 2016, by and between SILICON VALLEY BANK, a California corporation, with its principal place of business at 3003 Tasman Drive, Santa Clara, California 95054 and with a loan production office located at 275 Grove Street, Suite 2-200, Newton, M
June 15, 2016	EX-99.1	AEGERION PHARMACEUTICALS AND QLT INC. AGREE TO STRATEGIC MERGER —Strategic Merger Creates Well-Capitalized, Global Biopharmaceutical Organizations with Diverse Portfolio of Two Commercialized Rare Disease Programs and a Phase 3 Ready Ultra-Orphan Dev Exhibit 99.1 AEGERION PHARMACEUTICALS AND QLT INC. AGREE TO STRATEGIC MERGER ?Strategic Merger Creates Well-Capitalized, Global Biopharmaceutical Organizations with Diverse Portfolio of Two Commercialized Rare Disease Programs and a Phase 3 Ready Ultra-Orphan Development Program Addressing Significant Unmet Medical Need? ?Broad-Based Investor Syndicate to Vote in Favor of the Merger and Provide Co
June 15, 2016	EX-99.3	Dear Aegerion Colleagues, Exhibit 99.3 Dear Aegerion Colleagues, This morning we announced that Aegerion and QLT will merge to create a global, rare disease company called Novelion Therapeutics. This is an exciting and historic day and I hope that you take pride in your hard work and dedication to all our stakeholders which have enabled us to achieve this goal. We now expect to have the capital, breadth and capabilities to
June 15, 2016	EX-99.3	Dear Aegerion Colleagues, Exhibit 99.3 Dear Aegerion Colleagues, This morning we announced that Aegerion and QLT will merge to create a global, rare disease company called Novelion Therapeutics. This is an exciting and historic day and I hope that you take pride in your hard work and dedication to all our stakeholders which have enabled us to achieve this goal. We now expect to have the capital, breadth and capabilities to
June 15, 2016	EX-10.1	VOTING AGREEMENT EX-10.1 4 a16-133801ex10d1.htm EX-10.1 Exhibit 10.1 VOTING AGREEMENT This VOTING AGREEMENT (this “Voting Agreement”), dated as of June 14, 2016, by and between Aegerion Pharmaceuticals, Inc., a Delaware corporation (“Aegerion”), and [ ], a [ ] (the “Shareholder”). W I T N E S S E T H: WHEREAS, concurrently with the execution of this Voting Agreement, Aegerion, QLT Inc., a corporation incorporated
June 15, 2016	425	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2016 AEGERION PHARMACEUT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2016 AEGERION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34921 20-2960116 (State or other jurisdiction (Commission File (I.R.S.
June 15, 2016	EX-10.1	VOTING AGREEMENT Exhibit 10.1 VOTING AGREEMENT This VOTING AGREEMENT (this ?Voting Agreement?), dated as of June 14, 2016, by and between Aegerion Pharmaceuticals, Inc., a Delaware corporation (?Aegerion?), and [ ], a [ ] (the ?Shareholder?). W I T N E S S E T H: WHEREAS, concurrently with the execution of this Voting Agreement, Aegerion, QLT Inc., a corporation incorporated under the laws of British Columbia (?QL
June 15, 2016	EX-99.1	AEGERION PHARMACEUTICALS AND QLT INC. AGREE TO STRATEGIC MERGER —Strategic Merger Creates Well-Capitalized, Global Biopharmaceutical Organizations with Diverse Portfolio of Two Commercialized Rare Disease Programs and a Phase 3 Ready Ultra-Orphan Dev EX-99.1 10 a16-133801ex99d1.htm EX-99.1 Exhibit 99.1 AEGERION PHARMACEUTICALS AND QLT INC. AGREE TO STRATEGIC MERGER —Strategic Merger Creates Well-Capitalized, Global Biopharmaceutical Organizations with Diverse Portfolio of Two Commercialized Rare Disease Programs and a Phase 3 Ready Ultra-Orphan Development Program Addressing Significant Unmet Medical Need— —Broad-Based Investor Syndicate to Vo
June 15, 2016	EX-10.4	SUBORDINATION AGREEMENT Exhibit 10.4 SUBORDINATION AGREEMENT This Subordination Agreement (the ?Agreement?) is made as of June 14, 2016, by and between QLT INC. (?Creditor?), and SILICON VALLEY BANK, a California corporation, with its principal place of business at 3003 Tasman Drive, Santa Clara, California 95054 (?Bank?). Recitals A. Aegerion Pharmaceuticals, Inc., a Delaware corporation with its chief executive office
June 15, 2016	EX-10.2	LOAN AND SECURITY AGREEMENT Exhibit 10.2 LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT (this ?Agreement?) dated as of June 14, 2016, between QLT INC. a corporation incorporated under the laws of British Columbia (?QLT?), and AEGERION PHARMACEUTICALS, INC., a Delaware corporation (?Borrower?), provides the terms on which QLT shall lend to Borrower and Borrower shall repay QLT. The parties agree as follows: 1 AC
June 15, 2016	EX-10.5	FOURTH AMENDMENT TO FORBEARANCE AGREEMENT Exhibit 10.5 FOURTH AMENDMENT TO FORBEARANCE AGREEMENT THIS FOURTH AMENDMENT TO FORBEARANCE AGREEMENT (this ?Amendment?) is made as of this 8th day of June, 2016 by and between SILICON VALLEY BANK, a California corporation, with its principal place of business at 3003 Tasman Drive, Santa Clara, California 95054 and with a loan production office located at 275 Grove Street, Suite 2-200, Newton, Mas
June 15, 2016	EX-10.6	FIFTH AMENDMENT TO FORBEARANCE AGREEMENT Exhibit 10.6 FIFTH AMENDMENT TO FORBEARANCE AGREEMENT THIS FIFTH AMENDMENT TO FORBEARANCE AGREEMENT (this ?Amendment?) is made as of this 14th day of June, 2016 by and between SILICON VALLEY BANK, a California corporation, with its principal place of business at 3003 Tasman Drive, Santa Clara, California 95054 and with a loan production office located at 275 Grove Street, Suite 2-200, Newton, Mass
June 15, 2016	EX-3.1	AMENDED AND RESTATED AEGERION PHARMACEUTICALS, INC. (the “Corporation”) ARTICLE I Exhibit 3.1 AMENDED AND RESTATED BY-LAWS OF AEGERION PHARMACEUTICALS, INC. (the ?Corporation?) ARTICLE I Stockholders SECTION 1. Annual Meeting. The annual meeting of stockholders (any such meeting being referred to in these by-laws as an ?Annual Meeting?) shall be held at the hour, date and place within or without the United States which is fixed by the Board of Directors, which time, date and pl
June 15, 2016	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2016 AEGERION PHARMACEUT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2016 AEGERION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34921 20-2960116 (State or other jurisdiction (Commission File (I.R.S.
June 15, 2016	EX-99.2	THOMSON REUTERS STREETEVENTS Exhibit 99.2 THOMSON REUTERS STREETEVENTS EDITED TRANSCRIPT AEGR - Aegerion Pharmaceuticals Inc & QLT Inc Agree to Strategic Merger Call EVENT DATE/TIME: JUNE 15, 2016 / 12:30PM GMT 1 THOMSON REUTERS STREETEVENTS \| www.streetevents.com \| Contact Us ? 2016 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is proh
June 15, 2016	EX-3.1	AMENDED AND RESTATED AEGERION PHARMACEUTICALS, INC. (the “Corporation”) ARTICLE I Exhibit 3.1 AMENDED AND RESTATED BY-LAWS OF AEGERION PHARMACEUTICALS, INC. (the ?Corporation?) ARTICLE I Stockholders SECTION 1. Annual Meeting. The annual meeting of stockholders (any such meeting being referred to in these by-laws as an ?Annual Meeting?) shall be held at the hour, date and place within or without the United States which is fixed by the Board of Directors, which time, date and pl
June 15, 2016	EX-99.2	THOMSON REUTERS STREETEVENTS Exhibit 99.2 THOMSON REUTERS STREETEVENTS EDITED TRANSCRIPT AEGR - Aegerion Pharmaceuticals Inc & QLT Inc Agree to Strategic Merger Call EVENT DATE/TIME: JUNE 15, 2016 / 12:30PM GMT 1 THOMSON REUTERS STREETEVENTS \| www.streetevents.com \| Contact Us ? 2016 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is proh
June 15, 2016	EX-10.6	FIFTH AMENDMENT TO FORBEARANCE AGREEMENT Exhibit 10.6 FIFTH AMENDMENT TO FORBEARANCE AGREEMENT THIS FIFTH AMENDMENT TO FORBEARANCE AGREEMENT (this ?Amendment?) is made as of this 14th day of June, 2016 by and between SILICON VALLEY BANK, a California corporation, with its principal place of business at 3003 Tasman Drive, Santa Clara, California 95054 and with a loan production office located at 275 Grove Street, Suite 2-200, Newton, Mass
June 15, 2016	EX-10.4	SUBORDINATION AGREEMENT EX-10.4 7 a16-133801ex10d4.htm EX-10.4 Exhibit 10.4 SUBORDINATION AGREEMENT This Subordination Agreement (the “Agreement”) is made as of June 14, 2016, by and between QLT INC. (“Creditor”), and SILICON VALLEY BANK, a California corporation, with its principal place of business at 3003 Tasman Drive, Santa Clara, California 95054 (“Bank”). Recitals A. Aegerion Pharmaceuticals, Inc., a Delaware corpo
June 15, 2016	EX-10.3	SEVENTH LOAN MODIFICATION AGREEMENT EX-10.3 6 a16-133801ex10d3.htm EX-10.3 Exhibit 10.3 SEVENTH LOAN MODIFICATION AGREEMENT This Seventh Loan Modification Agreement (this “Loan Modification Agreement”) is entered into as of June 14, 2016, by and between SILICON VALLEY BANK, a California corporation, with its principal place of business at 3003 Tasman Drive, Santa Clara, California 95054 and with a loan production office located at 2
June 15, 2016	EX-10.2	LOAN AND SECURITY AGREEMENT EX-10.2 5 a16-133801ex10d2.htm EX-10.2 Exhibit 10.2 LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT (this “Agreement”) dated as of June 14, 2016, between QLT INC. a corporation incorporated under the laws of British Columbia (“QLT”), and AEGERION PHARMACEUTICALS, INC., a Delaware corporation (“Borrower”), provides the terms on which QLT shall lend to Borrower and Borrower shall repay
June 15, 2016	EX-2.1	AGREEMENT AND PLAN OF MERGER BY AND AMONG AEGERION PHARMACEUTICALS, INC., QLT INC. ISOTOPE ACQUISITION CORP. June 14, 2016 Exhibit 2.1 AGREEMENT AND PLAN OF MERGER BY AND AMONG AEGERION PHARMACEUTICALS, INC., QLT INC. AND ISOTOPE ACQUISITION CORP. June 14, 2016 TABLE OF CONTENTS Page ARTICLE I INTERPRETATION 2 1.1 Currency 2 1.2 Interpretation Not Affected by Headings 2 1.3 Knowledge and Disclosure 2 1.4 Extended Meanings, Etc. 2 1.5 Date of Any Action 3 1.6 Definitions 3 ARTICLE II THE MERGER 3 2.1 The Merger 3 2.2 T
June 15, 2016	EX-2.1	AGREEMENT AND PLAN OF MERGER BY AND AMONG AEGERION PHARMACEUTICALS, INC., QLT INC. ISOTOPE ACQUISITION CORP. June 14, 2016 Exhibit 2.1 AGREEMENT AND PLAN OF MERGER BY AND AMONG AEGERION PHARMACEUTICALS, INC., QLT INC. AND ISOTOPE ACQUISITION CORP. June 14, 2016 TABLE OF CONTENTS Page ARTICLE I INTERPRETATION 2 1.1 Currency 2 1.2 Interpretation Not Affected by Headings 2 1.3 Knowledge and Disclosure 2 1.4 Extended Meanings, Etc. 2 1.5 Date of Any Action 3 1.6 Definitions 3 ARTICLE II THE MERGER 3 2.1 The Merger 3 2.2 T
June 9, 2016	S-3/A	Aegerion Pharmaceuticals S-3/A S-3/A 1 a2228910zs-3a.htm S-3/A Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents As filed with the Securities and Exchange Commission on June 9, 2016 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 AEGERION PHARMACEUTICALS, INC. (Exact name of registrant as
June 9, 2016	CORRESP	Aegerion Pharmaceuticals ESP June 9, 2016 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.
June 8, 2016	CORRESP	Aegerion Pharmaceuticals ESP ROPES & GRAY LLP PRUDENTIAL TOWER 800 BOYLSTON STREET BOSTON, MA 02199-3600 WWW.ROPESGRAY.COM June 8, 2016 Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Suzanne Hayes, Assistant Director, Office of Healthcare and Insurance Re: Aegerion Pharmaceuticals, Inc. SEC Comment Letter dated June 6, 2016 Registration Statement on Form
June 7, 2016	EX-24	EX-24 POWER OF ATTORNEY The undersigned hereby constitutes and appoints Gregory Perry, Benjamin Harshbarger and Jennifer Fitzpatrick, with full power of substitution, as the undersigned's true and lawful attorney-in-fact to: (1) prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the U.
June 1, 2016	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2016 AEGERION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34921 20-2960116 (State or other jurisdiction of incorporation) (Commis
May 31, 2016	CORRESP	Aegerion Pharmaceuticals ESP ROPES & GRAY LLP PRUDENTIAL TOWER 800 BOYLSTON STREET BOSTON, MA 02199-3600 WWW.ROPESGRAY.COM May 31, 2016 Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Suzanne Hayes, Assistant Director, Office of Healthcare and Insurance Re: Aegerion Pharmaceuticals, Inc. SEC Comment Letter dated May 26, 2016 Registration Statement on Form
May 20, 2016	DEL AM	Aegerion Pharmaceuticals DEL AM AEGERION PHARMACEUTICALS, INC. One Main Street, Suite 800 Cambridge, Massachusetts 02142 May 20, 2016 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Re: Aegerion Pharmaceuticals, Inc. Registration Statement on Form S-3 (File No. 333-211462) Ladies and Gentlemen: Reference is made to the Registration Statement on Fo
May 19, 2016	S-8	Aegerion Pharmaceuticals S-8 As filed with the Securities and Exchange Commission on May 19, 2016 Registration No.
May 19, 2016	S-3	As filed with the Securities and Exchange Commission on May 19, 2016 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 AEGERION PHARMACEUTICALS, INC. (Exact name o Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents As filed with the Securities and Exchange Commission on May 19, 2016 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
May 19, 2016	EX-12.1	STATEMENT REGARDING COMPUTATION OF RATIO/DEFICIENCY OF EARNINGS TO FIXED CHARGES (in thousands) Exhibit 12.1 STATEMENT REGARDING COMPUTATION OF RATIO/DEFICIENCY OF EARNINGS TO FIXED CHARGES (in thousands) Three months ended Fiscal Year Ended December 31, March 31, 2016 2015 2014 2013 2012 2011 Fixed charges: Interest expense on indebtedness $ 7,231 $ 27,632 $ 9,938 $ 722 $ 937 $ 1,114 Interest portion of rental expense 293 762 350 163 90 22 $ 7,524 $ 28,394 $ 10,288 $ 885 $ 1,027 $ 1,136 Los
May 19, 2016	EX-4.2	AEGERION PHARMACEUTICALS, INC. Dated as of SENIOR DEBT SECURITIES EX-4.2 2 a2228697zex-42.htm EX-4.2 Exhibit 4.2 AEGERION PHARMACEUTICALS, INC. and Trustee INDENTURE Dated as of SENIOR DEBT SECURITIES CROSS-REFERENCE TABLE(1) Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(
May 19, 2016	EX-4.3	AEGERION PHARMACEUTICALS, INC. Dated as of SUBORDINATED DEBT SECURITIES Exhibit 4.3 AEGERION PHARMACEUTICALS, INC. and Trustee INDENTURE Dated as of SUBORDINATED DEBT SECURITIES CROSS-REFERENCE TABLE(1) Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a) 4.
May 16, 2016	EX-99.1	AEGERION PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2016 FINANCIAL RESULTS aegrEX991 Exhibit 99.1 AEGERION PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2016 FINANCIAL RESULTS Company records $35.7 million in total net product sales Company now expects full-year revenues for JUXTAPID to be between $90 million and $100 million Company continues to expect full-year revenues for MYALEPT to be between $40 million and $50 million Cambridge, MA, May 16, 2016 - Aegerion Pharmaceutica
May 16, 2016	8-K	Aegerion Pharmaceuticals 8-K (Current Report/Significant Event) aegrCurrent folio8kearningsrelease UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.
May 16, 2016	EX-10.2	AMENDMENT NO. 2 TO EMPLOYMENT AGREEMENT EX-10.2 3 aegr-20160331ex102a5f962.htm EX-10.2 Exhibit 10.2 AMENDMENT NO. 2 TO EMPLOYMENT AGREEMENT This Amendment No. 2 to Employment Agreement (the “Second Amendment”) is made and entered into as of May 3, 2016 by and between Aegerion Pharmaceuticals, Inc., a Delaware corporation (the “Company”) and Gregory Perry (the “Employee”), and effective as of February 12, 2016. Capitalized terms not defi
May 16, 2016	EX-10.3	[Remainder of this page left intentionally blank.] EX-10.3 4 aegr-20160331ex1033e9e56.htm EX-10.3 Exhibit 10.3 March 4, 2016 Via Email Mark Sumeray Dear Mark: As we have discussed, your employment with Aegerion Pharmaceuticals, Inc. (the “Company”) has terminated effective as of January 28, 2016 (the “Separation Date”). The purpose of this letter agreement (the “Agreement”) is to confirm the agreement between you and the Company concerning your se
May 16, 2016	10-Q	Aegerion Pharmaceuticals 10-Q (Quarterly Report) aegrCurrent Folio10Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.
May 16, 2016	EX-10.1	AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Exhibit 10.1 AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The purpose of this Amended and Restated Non-Employee Director Compensation Policy (this “Policy”) of Aegerion Pharmaceuticals, Inc., a Delaware corporation (the “Corporation”), is to provide a total compensation package that enables the Corporation to attract and retain, on a long-term basis, high caliber directors who ar
May 12, 2016	8-K	Financial Statements and Exhibits, Other Events 8-K 1 a16-1107438k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2016 AEGERION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34921 20-2960116 (State or other jurisdictio
May 12, 2016	EX-99.1	AEGERION PHARMACEUTICALS ANNOUNCES PRELIMINARY AGREEMENTS IN PRINCIPLE WITH DOJ AND SEC RELATED TO ONGOING INVESTIGATIONS Exhibit 99.1 AEGERION PHARMACEUTICALS ANNOUNCES PRELIMINARY AGREEMENTS IN PRINCIPLE WITH DOJ AND SEC RELATED TO ONGOING INVESTIGATIONS Cambridge, Mass. ? May 12, 2016 ? Aegerion Pharmaceuticals, Inc. (?Aegerion? or the ?Company?) (NASDAQ: AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, annou
May 11, 2016	NT 10-Q	Aegerion Pharmaceuticals NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 001-34921 CUSIP NUMBER 00767E 102 (Check one): o Form 10-K o Form 20-F o Form 11-K x Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: March 31, 2016 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Trans
May 3, 2016	DEFA14A	Aegerion Pharmaceuticals DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin
April 29, 2016	DEF 14A	Aegerion Pharmaceuticals DEF 14A QuickLinks - Click here to rapidly navigate through this document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
March 22, 2016	EX-1	AMENDMENT TO AGREEMENT EXECUTION COPY AMENDMENT TO AGREEMENT This AMENDMENT (the “Amendment”) is made as of March 21, 2016, by and among AEGERION Pharmaceuticals, Inc.
March 22, 2016	8-K	Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2016 AEGERION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34921 20-2960116 (State or other jurisdiction of incorporation) (Comm
March 22, 2016	SC 13D/A	AEGR / Aegerion Pharmaceuticals, Inc. / Sarissa Capital Management LP - SCHEDULE 13D/A, #5 Activist Investment SC 13D/A 1 sarissa13da5.htm SCHEDULE 13D/A, #5 CUSIP No. 00767E102 Page 1 of 3 Pages SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5)* Aegerion Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 00767E102 (CUSIP Number) Mark DiPaolo General
March 18, 2016	SC 13G	AEGR / Aegerion Pharmaceuticals, Inc. / Athyrium Opportunities II Acquisition LP - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to Rules 13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to Rule 13d-2(b) (Amendment No.
March 15, 2016	10-K	Aegerion Pharmaceuticals 10-K (Annual Report) 10-K 1 aegr-20151231x10k.htm 10-K Table of Contents U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015 ◻TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission
March 15, 2016	EX-10.50	AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Exhibit 10.50 AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The purpose of this Amended and Restated Non-Employee Director Compensation Policy (this “Policy”) of Aegerion Pharmaceuticals, Inc., a Delaware corporation (the “Corporation”), is to provide a total compensation package that enables the Corporation to attract and retain, on a long-term basis, high caliber directors who a
March 15, 2016	EX-10.44	AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT EX-10.44 4 aegr-20151231ex1044be9a7.htm EX-10.44 Exhibit 10.44 AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT This Amendment No. 1 to Employment Agreement (this “Amendment”), is entered into as of November 5, 2015, by and between Aegerion Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Gregory Perry (the “Employee”). WHEREAS, Employee and Company are parties to that certain Employment
March 15, 2016	EX-10.49	THIRD AMENDMENT TO FORBEARANCE AGREEMENT EXHIBIT 10.49 THIRD AMENDMENT TO FORBEARANCE AGREEMENT THIS THIRD AMENDMENT TO FORBEARANCE AGREEMENT (this “Amendment”) is made as of this 26th day of February, 2016 by and between SILICON VALLEY BANK, a California corporation, with its principal place of business at 3003 Tasman Drive, Santa Clara, California 95054 and with a loan production office located at 275 Grove Street, Suite 2-200, Newton,
March 15, 2016	EX-10.48	SECOND AMENDMENT TO FORBEARANCE AGREEMENT Exhibit 10.48 SECOND AMENDMENT TO FORBEARANCE AGREEMENT THIS SECOND AMENDMENT TO FORBEARANCE AGREEMENT (this “Amendment”) is made as of this 7th day of January, 2016 by and between SILICON VALLEY BANK, a California corporation, with its principal place of business at 3003 Tasman Drive, Santa Clara, California 95054 and with a loan production office located at 275 Grove Street, Suite 2-200, Newton,
March 15, 2016	EX-10.46	Acknowledgment of Indebtedness FORBEARANCE AGREEMENT Exhibit 10.46 THIS FORBEARANCE AGREEMENT (this “Agreement”) made as of this 9th day of November, 2015 by and between SILICON VALLEY BANK, a California corporation, with its principal place of business at 3003 Tasman Drive, Santa Clara, California 95054 and with a loan production office located at 275 Grove Street, Suite 2-200, Newton, Massachusetts 02466 (“Bank”) and AEGERION
March 15, 2016	EX-10.39	[Remainder of this page left intentionally blank.] EX-10.39 3 aegr-20151231ex10393d68e.htm EX-10.39 Exhibit 10.39 July 28, 2015 BY EMAIL Craig E. Fraser Dear Craig: As we have discussed, your employment with Aegerion Pharmaceuticals, Inc. (the “Company”) has terminated effective as of July 26, 2015 (the “Separation Date”). The purpose of this letter agreement (the “Agreement”) is to confirm the agreement between you and the Company concerning your
March 15, 2016	EX-10.38	[Remainder of this page left intentionally blank] Exhibit 10.38 July 28, 2015 BY EMAIL Marc Beer Dear Marc: As we have discussed, your employment with Aegerion Pharmaceuticals, Inc. (the “Company”) has terminated effective as of July 26, 2015 (the “Separation Date”). The purpose of this letter agreement (the “Agreement”) is to confirm the agreement between you and the Company concerning your separation from employment and severance benefits, as f
March 15, 2016	EX-10.45	Mark Sumeray Temporary Assignment Plan EX-10.45 5 aegr-20151231ex1045ea082.htm EX-10.45 Exhibit 10.45 Mark Sumeray Temporary Assignment Plan In order to provide strategic support to the European business during a critical time of reimbursement, pricing, and launch of Lojuxta in addition to Myalept registration and prelaunch planning, Aegerion has agreed to a temporary assignment, not to exceed one year, for Dr. Mark Sumeray in Germany.
March 15, 2016	EX-10.47	FIRST AMENDMENT TO FORBEARANCE AGREEMENT Exhibit 10.47 FIRST AMENDMENT TO FORBEARANCE AGREEMENT THIS FIRST AMENDMENT TO FORBEARANCE AGREEMENT (this “Amendment”) is made as of this 7th day of December, 2015 by and between SILICON VALLEY BANK, a California corporation, with its principal place of business at 3003 Tasman Drive, Santa Clara, California 95054 and with a loan production office located at 275 Grove Street, Suite 2-200, Newton,
March 10, 2016	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 5, 2016 AEGERION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34921 20-2960116 (State or other jurisdiction of incorporation) (Commi
March 10, 2016	10-K/A	Aegerion Pharmaceuticals 10-K/A (Annual Report) U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K/A Amendment No. 2 (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2014 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file Number: 001-34921 AEGERION
March 7, 2016	SC 13G	AEGR / Aegerion Pharmaceuticals, Inc. / ARMISTICE CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
February 29, 2016	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Other Events 8-K 1 a16-547518k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2016 AEGERION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34921 20-2960116 (State or other jurisdi
February 29, 2016	NT 10-K	Aegerion Pharmaceuticals NT 10-K SEC FILE NUMBER 001-34921 CUSIP NUMBER 00767E 102 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
February 25, 2016	EX-99.1	AEGERION PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2015 FINANCIAL RESULTS aegrEX991 Exhibit 99.1 AEGERION PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2015 FINANCIAL RESULTS Company records total net product sales of $49.0 million and $239.9 million in fourth quarter and full year of 2015, respectively- Cambridge, MA, February 25, 2016 - Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR), a biopharmaceutical company dedicated to the development and commercializatio
February 25, 2016	8-K	Aegerion Pharmaceuticals 8-K (Current Report/Significant Event) aegrCurrent folio8kearningsrelease UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.
February 17, 2016	8-K/A	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8-K/A 1 a16-407528ka.htm 8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A Amendment No. 1 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 28, 2016 AEGERION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34921 20-2960116 (
February 16, 2016	EX-99.1	JOINT FILING AGREEMENT Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessi
February 16, 2016	SC 13G/A	AEGR / Aegerion Pharmaceuticals, Inc. / SCOPIA CAPITAL MANAGEMENT LP Passive Investment STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
February 16, 2016	SC 13G/A	Aegerion Pharmaceuticals AMENDMENT NO. 2 (Passive Acquisition of More Than 5% of Shares) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* AEGERION PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, Par Value $0.001 Per Share (Title of Class of Securities) 00767E102 (CUSIP Number) December 31, 2015 (Date of Event which Requires Filing of this Statement) Check the appropriate box to design
February 12, 2016	SC 13G/A	AEGR / Aegerion Pharmaceuticals, Inc. / STONEPINE CAPITAL, L.P. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Aegerion Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 00767E102 (CUSIP Number) December 31, 2015 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whi
February 11, 2016	8-K	Aegerion Pharmaceuticals 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 7, 2016 AEGERION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34921 20-2960116 (State or other jurisdiction of incorporation) (Co
February 10, 2016	SC 13G/A	AEGR / Aegerion Pharmaceuticals, Inc. / VANGUARD GROUP INC Passive Investment aegerionpharmaceuticalsinc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2 )* Name of issuer: Aegerion Pharmaceuticals Inc Title of Class of Securities: Common Stock CUSIP Number: 00767E102 Date of Event Which Requires Filing of this Statement: December 31, 2015 Check
February 5, 2016	SC 13G/A	AEGR / Aegerion Pharmaceuticals, Inc. / WESTFIELD CAPITAL MANAGEMENT CO LP - WESTFIELD CAPITAL MANAGEMENT COMPANY, L.P. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* AEGERION PHARMACEUTICALS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 00767E102 (CUSIP Number) December 31, 2015 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whi
February 3, 2016	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8-K 1 a16-345318k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 28, 2016 AEGERION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34921 20-2960116 (State or other jurisdic
January 11, 2016	EX-99.1	Aegerion Pharmaceuticals Reports Preliminary 2015 Net Product Sales and Other Business Updates - 2015 Total Net Product Sales Expected to be Between $236.5 and $239.5 Million EX-99.1 Exhibit 99.1 Aegerion Pharmaceuticals Reports Preliminary 2015 Net Product Sales and Other Business Updates - 2015 Total Net Product Sales Expected to be Between $236.5 and $239.5 Million Cambridge, MA, January 11, 2016 - Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with de
January 11, 2016	EX-10.1	EMPLOYMENT AGREEMENT EX-10.1 Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (this ?Agreement?) is made and entered into as of this 7th day of January 2016, by and between Aegerion Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), and Mary T. Szela (the ?Employee?). W I T N E S S E T H : WHEREAS, the Company desires to employ Employee as its Chief Executive Officer and Employee desires to acce
January 11, 2016	EX-99.2	AEGERION PHARMACEUTICALS APPOINTS MARY SZELA AS CHIEF EXECUTIVE OFFICER Sandford D. Smith Appointed as Chairman of Aegerion’s Board of Directors EX-99.2 4 d108787dex992.htm EX-99.2 Exhibit 99.2 FOR IMMEDIATE RELEASE AEGERION PHARMACEUTICALS APPOINTS MARY SZELA AS CHIEF EXECUTIVE OFFICER Sandford D. Smith Appointed as Chairman of Aegerion’s Board of Directors Cambridge, MA, January 7, 2016 - Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies f
January 11, 2016	EX-24	EX-24 POWER OF ATTORNEY The undersigned hereby constitutes and appoints Benjamin Harshbarger, Jennifer Fitzpatrick and David Fine, with full power of substitution, as the undersigned's true and lawful attorney-in-fact to: (1) prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the U.
January 11, 2016	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events 8-K 1 d108787d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2016 AEGERION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34921 20-2960116 (State or other juris
January 5, 2016	SC 13G/A	AEGR / Aegerion Pharmaceuticals, Inc. / INTEGRATED CORE STRATEGIES (US) LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 2) AEGERION PHARMACEUTICALS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 00767E102 (CUSIP Number) DECEMBER 31, 2015 (Date of event which requires filing of this statement) Check the appropriate box to designa
December 7, 2015	8-K	Aegerion Pharmaceuticals 8-K (Current Report/Significant Event) aegrfolio8kSVB forbearance amend UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.
December 2, 2015	EX-24	EX-24 POWER OF ATTORNEY The undersigned hereby constitutes and appoints Benjamin Harshbarger, Gregory Perry, Jennifer Fitzpatrick and Marc Rubenstein, with full power of substitution, as the undersigned's true and lawful attorney-in-fact to: (1) prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the U.
November 13, 2015	SC 13G/A	Aegerion Pharmaceuticals 3G/A (Passive Acquisition of More Than 5% of Shares) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
November 10, 2015	8-K	Aegerion Pharmaceuticals 8-K (Current Report/Significant Event) aegrfolio8kEmployment Agreements UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.
November 9, 2015	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2015 Commission File Number 001-349 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2015 Commission File Number 001-34921 AEGERION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) DELAWARE 20-2960116 (State or other jurisdi
November 9, 2015	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 aegr-20151109x8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): November 9, 2015 AEGERION PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-34921 22-2960116 (State of Other Jur
November 9, 2015	EX-10.1	EMPLOYMENT AGREEMENT EX-10.1 2 aegr-20150930ex101f352ed.htm EX-10.1 Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is made as of the 21st day of August 2015, between Aegerion Pharmaceuticals, Inc. a Delaware corporation (the “Company”), and Sandford D. Smith, an individual (the “Executive”) (together the “Parties”). WHEREAS, the Company desires to employ the Executive and the Executive desir
November 9, 2015	EX-99.1	AEGERION PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2015 FINANCIAL RESULTS aegrEX991 Exhibit 99.1 AEGERION PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2015 FINANCIAL RESULTS - Company records $67.3 million in total net product sales - Cambridge, MA, November 9, 2015 - Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, announced its
October 23, 2015	EX-1	CONFIDENTIALITY AGREEMENT Exhibit 1 CONFIDENTIALITY AGREEMENT Aegerion Pharmaceuticals, Inc. One Main Street, Suite 800 Cambridge, MA 02142 October 22, 2015 To: Each of the persons listed on Schedule A hereto (the ? Sarissa Group? or ? you?) Ladies and Gentlemen: This letter agreement shall become effective upon its execution by the parties hereto. Capitalized terms used but not otherwise defined herein shall have the mean
October 23, 2015	SC 13D/A	Aegerion Pharmaceuticals SCHEDULE 13D/A, #4 (Activist Acquisition of More Than 5% of Shares) CUSIP No. 00767E102 Page 1 of 3 Pages SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* Aegerion Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 00767E102 (CUSIP Number) Mark DiPaolo General Counsel Sarissa Capital Management LP 660 Steam
September 29, 2015	SC 13D/A	AEGR / Aegerion Pharmaceuticals, Inc. / Sarissa Capital Management LP - SCHEDULE 13D/A, AMENDMENT NO. 3 Activist Investment CUSIP No. 00767E102 Page 1 of 9 Pages SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Aegerion Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 00767E102 (CUSIP Number) Mark DiPaolo General Counsel Sarissa Capital Management LP 660 Steam
September 23, 2015	EX-10.1	AMENDED AND RESTATED INDUCEMENT AWARD STOCK OPTION PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS EX-10.1 2 d64555dex101.htm EX-10.1 Exhibit 10.1 AMENDED AND RESTATED INDUCEMENT AWARD STOCK OPTION PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Aegerion Pharmaceuticals, Inc. Amended and Restated Inducement Award Stock Option Plan (the “Plan”), which amends and restates the Aegerion Pharmaceuticals, Inc. Inducement Award Stock Option Plan in effect October 1
September 23, 2015	EX-99.1	Donald K. Stern, Esq. Appointed to Aegerion Pharmaceuticals’ Board of Directors EX-99.1 Exhibit 99.1 Donald K. Stern, Esq. Appointed to Aegerion Pharmaceuticals? Board of Directors Cambridge, MA, September 18, 2015 - Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, has appointed Donald K. Stern, Esq., to its Board of Directors, eff
September 23, 2015	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits 8-K 1 d64555d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 17, 2015 AEGERION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34921 20-2960116 (State or other jur
September 18, 2015	EX-24	EX-24 POWER OF ATTORNEY The undersigned hereby constitutes and appoints Gregory Perry, Jennifer Fitzpatrick and Benjamin Harshbarger, with full power of substitution, as the undersigned's true and lawful attorney-in-fact to: (1) prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the U.
September 18, 2015	EX-24	EX-24 POWER OF ATTORNEY The undersigned hereby constitutes and appoints Gregory Perry, Jennifer Fitzpatrick and Marc Rubenstein, with full power of substitution, as the undersigned's true and lawful attorney-in-fact to: (1) prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the U.
September 4, 2015	EX-24	EX-24 POWER OF ATTORNEY The undersigned hereby constitutes and appoints Gregory Perry, Jennifer Fitzpatrick and Benjamin Harshbarger, with full power of substitution, as the undersigned's true and lawful attorney-in-fact to: (1) prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the U.
August 27, 2015	8-K/A	Aegerion Pharmaceuticals FORM 8-K AMENDMENT NO. 1 (Current Report/Significant Event) Form 8-K Amendment No. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A Amendment No. 1 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 21, 2015 AEGERION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34921 20-2960116 (State o
August 17, 2015	8-K/A	Financial Statements and Exhibits, Results of Operations and Financial Condition Form 8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A Amendment No. 1 CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): August 5, 2015 AEGERION PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-34921 22-2960116 (State of Other Jurisdi
August 17, 2015	EX-99.1	Aegerion Pharmaceuticals, Inc. Condensed Consolidated Statements of Operations Three Months Ended June 30, Six Months Ended June 30, (In 000s) 2015 2014 2015 2014 Net product sales $ 64,197 $ 36,014 $ 123,581 $ 62,987 Cost of product sales 13,997 4,1 EX-99.1 Exhibit 99.1 Aegerion Pharmaceuticals, Inc. Condensed Consolidated Statements of Operations (unaudited) Three Months Ended June 30, Six Months Ended June 30, (In 000s) 2015 2014 2015 2014 Net product sales $ 64,197 $ 36,014 $ 123,581 $ 62,987 Cost of product sales 13,997 4,158 25,835 6,822 Operating expenses: Selling, general and administrative 42,672 32,330 89,600 64,109 Research and deve
August 17, 2015	EX-10.1	EMPLOYMENT AGREEMENT EX-10.1 2 d943604dex101.htm EX-10.1 Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) is made and entered into as of this 26 day of March 2012, by and between Aegerion Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and William T. Andrews, MD, FACP (the “Employee”). W I T N E S S E T H : WHEREAS, the Company desires to employ Employee and to enter into t
August 17, 2015	EX-10.2	EMPLOYMENT AGREEMENT Exhibit 10.2 EMPLOYMENT AGREEMENT This Employment Agreement (this ?Agreement?) is made and entered into as of this 26th day of June 2015, by and between Aegerion Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), and Gregory Perry (the ?Employee?). W I T N E S S E T H : WHEREAS, the Company desires to employ Employee and to enter into this Agreement embodying the terms of such employme
August 17, 2015	EX-10.3	SIXTH LOAN MODIFICATION AGREEMENT EX-10.3 4 d943604dex103.htm EX-10.3 Exhibit 10.3 SIXTH LOAN MODIFICATION AGREEMENT This Sixth Loan Modification Agreement (this “Loan Modification Agreement”) is entered into as of August 7, 2015, by and between SILICON VALLEY BANK, a California corporation, with its principal place of business at 3003 Tasman Drive, Santa Clara, California 95054 and with a loan production office located at 275 Gro
August 17, 2015	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2015 Commission File Number 001-34921 AE 10-Q 1 d943604d10q.htm FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2015 Commission File Number 001-34921 AEGERION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) DELAWARE 20-296
August 11, 2015	8-K	Aegerion Pharmaceuticals FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2015 AEGERION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34921 20-2960116 (State or other jurisdiction of incorporati
August 11, 2015	NT 10-Q	Aegerion Pharmaceuticals NT 10-Q NT 10-Q 91SEC FILE NUMBER 001-34921 CUSIP NUMBER 00767E 102 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
August 5, 2015	EX-99.1	AEGERION PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS - Company records $64.2 million in total net product sales - - JUXTAPID® net product sales were $57.1 million in the second quarter of 2015, 96% from prescriptions written in th EX-99.1 Exhibit 99.1 AEGERION PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS - Company records $64.2 million in total net product sales - - JUXTAPID? net product sales were $57.1 million in the second quarter of 2015, 96% from prescriptions written in the U.S. - - Company reiterates 2015 total net product sales guidance of between $205 and $235 million - Cambridge, MA, August 5, 2
August 5, 2015	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 d93154d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): August 5, 2015 AEGERION PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-34921 22-2960116 (State of Other Jurisdiction
July 30, 2015	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 26, 2015 AEGERION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34921 20-2960116 (State or other jurisdiction of incorporatio
July 30, 2015	EX-99.1	AEGERION PHARMACEUTICALS ANNOUNCES LEADERSHIP CHANGES TO SUPPORT THE NEXT STAGE OF GROWTH Company reports preliminary second quarter 2015 total net product sales of between $63 and $64 million and preliminary cash and cash equivalents of approximatel EX-99.1 Exhibit 99.1 AEGERION PHARMACEUTICALS ANNOUNCES LEADERSHIP CHANGES TO SUPPORT THE NEXT STAGE OF GROWTH Company reports preliminary second quarter 2015 total net product sales of between $63 and $64 million and preliminary cash and cash equivalents of approximately $82 million as of June 30, 2015 Company to announce second quarter 2015 financial results on Wednesday, August 5 CAMBRIDGE, Mas
July 10, 2015	EX-24	EX-24 POWER OF ATTORNEY The undersigned hereby constitutes and appoints Anne Marie Cook and Jennifer Fitzpatrick, with full power of substitution, as the undersigned's true and lawful attorney-in-fact to: (1) prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the U.
July 7, 2015	EX-10.26	FIFTH LOAN MODIFICATION AGREEMENT EX-10.26 Exhibit 10.26 FIFTH LOAN MODIFICATION AGREEMENT This Fifth Loan Modification Agreement (this “Loan Modification Agreement”) is entered into as of January 9, 2015, by and between SILICON VALLEY BANK, a California corporation, with its principal place of business at 3003 Tasman Drive, Santa Clara, California 95054 and with a loan production office located at 275 Grove Street, Suite 2-200, N
July 7, 2015	EX-10.29	CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. ASSET PURCHASE AGREEMENT By and between Amylin Pharmaceuticals, LLC, AstraZeneca Pharmaceuticals LP (solel EX-10.29 3 d10636dex1029.htm EX-10.29 Exhibit 10.29 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. ASSET PURCHASE AGREEMENT By and between Amylin Pharmaceuticals, LLC, AstraZeneca Pharmaceuticals LP (solely for purposes of Sections 2.1.1, 2.2.1 and
July 7, 2015	10-K/A	U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K/A Amendment No. 1 U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K/A Amendment No. 1 (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2014 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file Number: 001-34921 AEGERION
June 29, 2015	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events, Submission of Matters to a Vote of Security Holders 8-K 1 d947811d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2015 AEGERION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34921 20-2960116 (State or other jurisdi
June 29, 2015	EX-99.1	Aegerion Pharmaceuticals Appoints Gregory Perry as Chief Financial Officer EX-99.1 Exhibit 99.1 Aegerion Pharmaceuticals Appoints Gregory Perry as Chief Financial Officer Cambridge, MA, June 25, 2015 - Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, announced the appointment of Gregory D. Perry as chief financial officer, eff
June 8, 2015	EX-24	EX-24 POWER OF ATTORNEY The undersigned hereby constitutes and appoints Anne Marie Cook and Jennifer Fitzpatrick, with full power of substitution, as the undersigned's true and lawful attorney-in-fact to: (1) prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the U.
May 29, 2015	8-K/A	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A Amendment No. 1 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2015 AEGERION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34921 20-2960116 (State or other jurisdiction of inco
May 29, 2015	SC 13G	AEGR / Aegerion Pharmaceuticals, Inc. / STONEPINE CAPITAL, L.P. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Aegerion Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 00767E102 (CUSIP Number) May 26, 2015 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which thi
May 21, 2015	SC 13D/A	AEGR / Aegerion Pharmaceuticals, Inc. / Sarissa Capital Management LP - SCHEDULE 13D/A, AMENDMENT NO. 2 Activist Investment CUSIP No. 00767E102 Page 1 of 8 Pages SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Aegerion Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 00767E102 (CUSIP Number) Mark DiPaolo General Counsel Sarissa Capital Management LP 660 Steam
May 14, 2015	EX-99.1	Aegerion Pharmaceuticals Announces Resignation of Chief Financial Officer Chief Accounting Officer David Aubuchon Appointed as Acting Chief Financial Officer EX-99.1 2 d926735dex991.htm EX-99.1 Exhibit 99.1 Aegerion Pharmaceuticals Announces Resignation of Chief Financial Officer Chief Accounting Officer David Aubuchon Appointed as Acting Chief Financial Officer Cambridge, MA, May 14, 2015 - Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients
May 14, 2015	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events 8-K 1 d926735d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2015 AEGERION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34921 20-2960116 (State or other jurisdic
May 8, 2015	EX-10.1	AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY EX-10.1 Exhibit 10.1 AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The purpose of this Amended and Restated Non-Employee Director Compensation Policy (this “Policy”) of Aegerion Pharmaceuticals, Inc., a Delaware corporation (the “Corporation”), is to provide a total compensation package that enables the Corporation to attract and retain, on a long-term basis, high caliber director
May 8, 2015	EX-10.2	AMENDED AND RESTATED EMPLOYMENT AGREEMENT EX-10.2 3 d896578dex102.htm EX-10.2 Exhibit 10.2 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (this “Agreement”) is made and entered into as of this 14 day of April 2015, by and between Aegerion Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Mary M. Weger (the “Employee”). W I T N E S S E T H : WHEREAS, the Company and Employee previo
May 8, 2015	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2015 Commission File Number 001-34921 A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2015 Commission File Number 001-34921 AEGERION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) DELAWARE 20-2960116 (State or other jurisdictio
May 7, 2015	DEFA14A	Aegerion Pharmaceuticals DEFA14A DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ?
May 4, 2015	EX-99.1	AEGERION PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2015 FINANCIAL RESULTS - Company records $59.4 million in total net product sales - - JUXTAPID® net product sales of $57.3 million in the first quarter of 2015 represents 112% growth over the first qua EX-99.1 Exhibit 99.1 AEGERION PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2015 FINANCIAL RESULTS - Company records $59.4 million in total net product sales - - JUXTAPID? net product sales of $57.3 million in the first quarter of 2015 represents 112% growth over the first quarter of 2014 - - 2015 total net product sales guidance reiterated at between $205 and $235 million? Cambridge, MA, May 4, 2015?Ae
May 4, 2015	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 d920159d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): May 4, 2015 AEGERION PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-34921 22-2960116 (State of Other Jurisdict
April 30, 2015	DEF 14A	Aegerion Pharmaceuticals DEF 14A DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x
April 20, 2015	PRE 14A	Aegerion Pharmaceuticals PRE 14A PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: x Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ?
April 10, 2015	EX-24	EX-24 POWER OF ATTORNEY The undersigned hereby constitutes and appoints Anne Marie Cook, with full power of substitution, as the undersigned's true and lawful attorney-in-fact to: (1) prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the U.
April 9, 2015	EX-99.1	Jorge Plutzky, M.D., Appointed to Aegerion Pharmaceuticals’ Board of Directors EX-99.1 Exhibit 99.1 Jorge Plutzky, M.D., Appointed to Aegerion Pharmaceuticals? Board of Directors Cambridge, MA, April 9, 2015?Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, has appointed Jorge Plutzky, M.D., to its Board of Directors, effective imm
April 9, 2015	8-K	Aegerion Pharmaceuticals FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 8, 2015 AEGERION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34921 22-2960116 (State or other jurisdiction of incorporatio
April 3, 2015	EX-24	EX-24 POWER OF ATTORNEY The undersigned hereby constitutes and appoints Anne Marie Cook, with full power of substitution, as the undersigned's true and lawful attorney-in-fact to: (1) prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the U.

AEGR / Aegerion Pharmaceuticals, Inc. - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

Mga Batayang Estadistika

SEC Filings

SEC Filings (Chronological Order)